Friday, October 16, 2026

Energy & Resources

2 articles

U.S. Solar Chief Faces Collapse Risk as Chinese Competition Exposes Policy Dependency

U.S. Solar Chief Faces Collapse Risk as Chinese Competition Exposes Policy Dependency

Suniva CEO Tony Etnyre faces a catastrophic-severity risk: U.S. domestic solar cell manufacturing is economically unviable without Section 201/301 tariffs and IRA tax credits. China's cost dominance in global solar production means American factories have no competitive fallback if either policy pillar is removed. For international investors with exposure to U.S. solar assets, the risk profile is binary — viability or collapse.

LM Salvado•
U.S. Bets on New York Graphite Mine to Break China's Stranglehold on Battery Supply Chains

U.S. Bets on New York Graphite Mine to Break China's Stranglehold on Battery Supply Chains

Titan Mining's Kilbourne Graphite Project in upstate New York is emerging as a flagship effort to reduce Western dependence on Chinese graphite, which dominates global supply of a mineral critical to electric vehicle batteries. Backed by $120 million in U.S. federal financing and boasting a $513 million after-tax NPV, the project targets 2027 construction and could supply roughly half of current U.S. natural graphite demand by itself. The development reflects a broader geopolitical push by Washi

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com